Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 7/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 7/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 7/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 6/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25173042 | 0.93 | PTGER1 (0.39) | PTGER4PTGER3PTGER2PTGER1FFAR1 | |
| SCHEMBL9171866 | 0.75 | PTGDR2 (0.39) | PTGER4PTGER3PTGER2PTGER1ALDH1A1 | |
| SCHEMBL31355071 | 0.75 | KMT2A (0.40) | KMT2ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3202976 | 0.75 | KMT2A (0.40) | KMT2ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3725510 | 0.74 | ALDH1A1 (0.35) | KMT2AALDH1A1LMNA | |
| SCHEMBL7432374 | 0.72 | ENPP2 (0.43) | FFAR1ALDH1A1LMNA | |
| SCHEMBL16718185 | 0.72 | KMT2A (0.43) | FFAR4KMT2ACYP2D6SLC6A2SLC6A4 | |
| SCHEMBL1001580 | 0.71 | KMT2A (0.45) | KMT2ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31355068 | 0.71 | GPR3 (0.41) | KMT2ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4600049 | 0.71 | GPR3 (0.41) | KMT2ACYP2D6SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | PTGER4 4297/4885PTGER3 4475/4885PTGER2 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.